2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 393-396
Technology and Procedures, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Genomics, Hematopoiesis, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Adult
PAPER

1065 Single-cell genotyping and methylomics resolves clonal hierarchies and epiclonal heterogeneity in normal and malignant hematopoiesis

Kyung Lock Kim, PhD, Maria Reyes Reyes Capilla-Guerra, MSc2, Priyal Desai3, Alexia C. Ferreira4, Wallace A. Bourgeois, MD5, Andrew A. Lane, MD, PhD6, Scott A Armstrong, MD, PhD7, Evan C. Chen, MD8, Gabriel Griffin, MD9
1 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
6 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center; Harvard Medical School, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Genetic and epigenetic evolution cooperatively drive leukemogenesis. However, their interplay remains poorly understood as existing single-cell multiomic technologies cannot efficiently capture DNA mutations and DNA methylation states genome-wide. To overcome this challenge, we previously introduced scGEM-seq (single-cell Genotyping and Methylation sequencing) as a scalable single-cell multiomic platform for integrated targeted genotyping and DNA methylation profiling. In brief, our method encapsulates single cells in semi-permeable capsules, followed by multiplex targeted amplification for genotyping, novel HexaDecimal split-pool barcoding, separation of genotyping and genomic DNA libraries, and enzymatic methyl (EM) conversion of the genomic DNA library prior to sequencing. Although the original implementation enabled high-throughput integrated analysis, genome-wide methylome coverage was too low (~30-50,000 CpGs per cell) to resolve heterogeneous cell-states in bone marrow samples from healthy donors and patients with leukemia.

We present an optimized implementation of scGEM-seq that combines EM conversion of unfragmented genomic DNA with subsequent whole-genome amplification, increasing methylome coverage to more than 2 million CpG sites per cell while maintaining high-efficiency targeted genotyping in approximately 90% of cells. First, we applied this improved scGEM-seq assay to 8,972 normal bone marrow cells from two healthy donors (one male, one female). This resolved 12 methylome-defined cell states spanning hematopoietic stem/progenitor cells through differentiated myeloid and lymphoid populations through stepwise changes in DNA methylation at specific regulatory elements. Differentiated cell-states were predominantly defined by genome-wide DNA hypomethylation in erythroid and cell-type specific DNA methylation remodeling at enhancers, promoters, and CpG islands in other hematopoietic lineages.

We next applied our optimized scGEM-seq assay to 17,204 cells from three acute leukemia patient samples to resolve genetic clones defined by pathogenic DNA mutations together with their associated epigenetic cell states. In one AML specimen harboring two TET2 mutations (TET2 p.S1039*, TET2 p.R1214W) together with JAK2, PTPN11, ASXL1, and KMT2A::AF6 alterations, integrated single-cell targeted genotyping and methylome profiling reconstructed branched clonal evolution initiated by TET2 co-mutant hematopoietic stem/progenitor cells. Two mutually exclusive evolutionary trajectories emerged from these premalignant founders: (1) TET2 → JAK2 p.V617F → PTPN11 p.Y63C and (2) TET2 → ASXL1 p.R965* →KMT2A::AF6. Notably, each of these clonal trajectories were accompanied by stepwise and distinctive changes in DNA methylation states. Notably, scGEM-seq distinguished TET2 co-mutated HSPCs from phenotypically similar normal HSPCs despite comparable global DNA methylation levels. Compared with normal HSPCs, myeloid-biased TET2 co-mutated HSPCs exhibited significant selective hypermethylation at enhancers, consistent with previous bulk studies, as well as at 3′ UTRs, and CpG shores, whereas promoter, 5′ UTR, CpG islands, gene bodies, and intergenic regions showed no significant methylation changes. Gene ontology analysis of genes linked with hypermethylated enhancers revealed significant enrichment of hematopoietic differentiation pathways, suggesting that TET2 loss impairs hematopoietic differentiation by preventing programmed DNA hypomethylation at key gene-regulatory elements. Finally, we performed methylome-based lineage tracing using a computational framework MethylTree to reconstruct epiclonal hierarchies and overlay these with genetic clonal hierarchies in patient samples. In particular, we found that genetic clones harboring TET2 loss showed a wider range of epiclones relative to TET2-wild-type cells, suggesting epiclonal diversification as a possible mechanism for the function of TET2 as a “founder” mutation during leukemogenesis.

scGEM-seq combines scalable single-cell targeted genotyping with high-resolution genome-wide methylome profiling, enabling simultaneous reconstruction of genetic clonal and epiclonal hierarchies. Together, these findings establish integrated genetic clonal and epiclonal hierarchies as a fundamental framework for understanding hematopoiesis and blood cancer evolution and provide a general strategy for dissecting how genetic and epigenetic evolution cooperate during cancer evolution.

Kyung Lock Kim, PhD: No relevant conflicts of interest to declare.